Taixiang Wu, J Bioequiv Availab 2011, 3:7
doi: http://dx.doi.org/10.4172/0975-0851.1000107

OMICS Group Conferences
Accelerating Scientific Discovery

International Conference & Exhibition on
Pharmaceutical Regulatory Affairs
6-7 September 2011 Baltimore, USA

Quality assurance system for Chinese clinical studies of Chinese clinical trials registry

Taixiang Wu

West China Hospital, Sichuan University, China

As a national public clinical trial registry and a recognized Primary Registry of WHO, Chinese Clinical Trial Registry (ChiCTR) takes the responsibility to dissimilate the knowledge of clinical trial transparency which is an important ethics issue of medical studies involving human, and to promote the quality of medical studies in China. The ChiCTR had developed three key points to ensure the quality of clinical studies include: 1. Register a clinical study involving human before recruiting the first participants; 2. Real-time monitoring system: eCRF public system; 3. Good reporting the results. We have developed ideas: 1. to register clinical studies is the ethics responsibility and obligation of trialists but not for the purpose of publication; 2. a clinical study is a public event itself which needs public population to participate, and the results may be used to public population service. Therefore, public have the right to know how the study is processing.

Biography

Taixiang Wu is the administrator of Chinese Clinical Trials Registry, a primary registry of WHO, a pioneer of clinical trial transparence in China. He has published more than 130 papers in reputed journals and serving as an editorial board member and peer reviewer of repute.